PRENW
Prenetics Global Limited
NASDAQ · Healthcare · Medical - Diagnostics & Research · HK
$0.01
−9.79%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 142.6M | 92.4M | 30.6M | 21.7M | 13.2M |
| Cost of Revenue | 53.3M | 43.6M | 15.2M | 12.9M | 9.5M |
| Gross Profit | 89.3M | 48.8M | 15.4M | 8.8M | 3.6M |
| Operating Expenses | |||||
| R&D Expense | 4.1M | 5.1M | 10.9M | 11.7M | 6.0M |
| SG&A Expense | 130.9M | 79.8M | 55.4M | 49.7M | 64.1M |
| General & Admin Expense | 43.6M | 45.7M | 46.7M | 41.4M | 59.3M |
| Selling & Marketing Expense | 87.3M | 34.0M | 8.6M | 8.2M | 4.7M |
| Other Expenses | 4.4M | 2.0M | (2.7M) | (606.8K) | (430.0K) |
| Total Operating Expenses | 139.4M | 86.9M | 63.5M | 60.7M | 69.6M |
| Cost and Expenses | 192.7M | 130.5M | 78.8M | 73.6M | 79.2M |
| Operating Income (EBIT) | (50.2M) | (38.1M) | (48.1M) | (51.9M) | (66.0M) |
| Non-Operating | |||||
| Interest Income | — | 1.0M | 2.0M | 3.9M | 472.0K |
| Interest Expense | 122.0K | 241.0K | 203.0K | 119.7K | 242.0K |
| Net Interest Income | (122.0K) | 801.0K | 1.8M | 3.8M | 230.0K |
| Other Non-Op Income/Expense | (21.4M) | 1.9M | (9.6M) | (4.8M) | (159.8M) |
| Non-Operating Income (excl Interest) | 16.5M | (2.2M) | 9.4M | 3.8M | 159.6M |
| EBT (Pre-Tax Income) | (71.5M) | (36.2M) | (57.7M) | (56.7M) | (225.8M) |
| Income Tax Expense | 85.0K | 34.0K | (7.9M) | (269.4K) | (245.0K) |
| Bottom Line | |||||
| Net Income | (67.6M) | (37.7M) | (46.3M) | (62.7M) | (190.5M) |
| Earnings from Cont. Ops | (71.6M) | (36.2M) | (49.8M) | (56.4M) | (225.6M) |
| Earnings from Discont. Ops | 2.7M | (3.7M) | 22.0K | (8.4M) | 35.1M |
| Bottom Line Net Income | (67.6M) | (37.7M) | (46.3M) | (62.7M) | (190.5M) |
| Per Share | |||||
| Basic EPS | ($4.16) | ($2.68) | ($3.64) | ($5.58) | ($37.57) |
| Diluted EPS | ($4.16) | ($2.68) | ($3.64) | ($5.58) | ($37.57) |
| Revenue Per Share | $8.26 | $6.57 | $2.41 | $1.93 | $2.60 |
| Shares | |||||
| Basic Shares Outstanding | 17.3M | 14.1M | 12.7M | 11.2M | 5.1M |
| Diluted Shares Outstanding | 17.3M | 14.1M | 12.7M | 11.2M | 5.1M |
| Profitability Metrics | |||||
| EBITDA | (62.5M) | (32.2M) | (51.6M) | (47.9M) | (218.0M) |
| D&A | 4.2M | 3.8M | 5.9M | 7.8M | 7.5M |
| EBIT | (66.7M) | (36.0M) | (57.5M) | (55.7M) | (225.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026